Ken Griffin Inventiva S.A. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$10.73 - $14.85 $173,031 - $239,471
-16,126 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$13.0 - $15.67 $429 - $517
33 Added 0.21%
16,126 $219,000
Q1 2021

May 17, 2021
SELL
$12.55 - $19.0 $64,896 - $98,249
-5,171 Reduced 24.32%
16,093 $237,000
Q4 2020

Feb 16, 2021
BUY
$11.35 - $14.5 $241,346 - $308,328
21,264 New
21,264 $308,000

Others Institutions Holding IVA

# of Institutions
8
Shares Held
4.85M
Call Options Held
0
Put Options Held
0
View Full List

About Inventiva S.A.

IVA Quotes by TradingView
  • Ticker IVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,134,200
  • Market Cap $93.1M
  • Description
  • Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company als...
More about IVA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email